N/A
N=40
Personalized Blood Flow Restriction for Anterior Cruciate Ligament Rehabilitation
Anterior Cruciate Ligament Tear
Bottom Line
View on ClinicalTrials.gov: NCT04635579 ↗Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Feb 2022
Primary outcome: Primary: Knee Flexion — -0.05; 0.01 Degrees
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Blood flow restriction (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Washington
- Primary completion
- Nov 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Knee Flexion |
-0.05; 0.01 | — |
| PRIMARY Knee Internal Rotation |
1.19; -0.03 | — |
| PRIMARY Knee Varus |
0.12; -0.36 | — |
| PRIMARY Hip Flexion |
-1.73; -2.9 | — |
| PRIMARY Hip Adduction |
0.61; 1.52 | — |
| PRIMARY Hip Internal Rotation |
1.49; 1.05 | — |
| PRIMARY Knee Extension Moment |
0.31; 0.6 | — |
| PRIMARY Knee Internal Rotation Moment |
-0.01; -0.02 | — |
| PRIMARY Knee Adduction Moment |
0.06; 0.12 | — |
| PRIMARY Hip Extension Moment |
0.09; 0.2 | — |
| PRIMARY Hip Adduction Moment |
-0.01; -0.07 | — |
| PRIMARY Hip Internal Rotation Moment |
-0.02; 0.05 | — |
| SECONDARY Exercise Difficulty Score |
4.0; 5.0 | — |
| SECONDARY Exercise Discomfort Score |
4.0; 4.5 | — |
Summary
This is a cross-sectional study on the use of personalized blood flow restriction during rehabilitation exercises and its effects on biomechanics on people who have had an anterior cruciate ligament reconstruction and healthy controls
Eligibility Criteria
Inclusion Criteria (ACL-R group):
- Must be undergoing rehabilitation for anterior cruciate ligament reconstruction surgery
- Must be at least 3 months post surgery.
- Attending clinician should confirm that they are able to take part in the trial
Exclusion Criteria
- Any other orthopaedic, neurological, or other condition within the last 12 months that would affect ability to carry out the required exercises
- Any medical conditions that may affect circulation including, but not limited to, deep vein thrombosis, high blood pressure, and cardiac disease
Data sourced from ClinicalTrials.gov (NCT04635579). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.